AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a trailblazing clinical-stage biopharmaceutical company speciali...
The deal, valued at up to $1.05 billion, comprises an $800 million upfront payment and an additional $250 million contingent upon r...
Biocon Biologics Limited, a fully integrated global biosimilars company and a subsidiary of Biocon Limited (BSE code: 532523, NSE: BIOCON),...
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneous...
– Proceeds will be used to complete clinical demonstration trials of the lead candidate drug RNDP-001 for the treatment of Parkinson's di...
Immediately after the effective time of the Acquisition, and before giving effect to the concurrent private placement the former stockholders of Bi...
ICIG acquires production facilities at five locations in Germany and U.S. Purchase price in low triple-digit million euro range Closing expected for mi...
In a bold move, Ricks emphasized the urgency for financial regulators to scrutinize the deal, pointing out Catalent's extensive client base, compri...
The acquisition encompasses key assets such as pelabresib, a promising late-stage BET inhibitor for myelofibrosis (MF), and tulmimetostat, an early-stage i...
In a strategic shift that promises to redefine the pharmaceutical industry, Novo Holdings, the investment arm of Novo Nordisk's parent foundation, has unve...
The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva.&nb...
ImpriMed, a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, announced the close of a $2...
Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial pro...
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneou...
© 2025 Biopharma Boardroom. All Rights Reserved.
